Related Experiment Video
Updated: Jul 8, 2026
08:48
A Rat Model of EcoHIV Brain Infection
Published on: January 21, 2021
HIV-1-Associated Cognitive-Motor Disorders: A Research-Based Approach to Diagnosis and Treatment
K Goodkin1, F L Wilkie, T T Baldewicz
1Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, FL, USA.
CNS Spectrums
|January 15, 2008
Summary
Diagnosing HIV-1 cognitive disorders requires ruling out other conditions and using standardized tests. Effective treatments target neuroprotection and include antiretroviral therapies, with ongoing research into inflammation and neurotransmitters.
Area of Science:
- Neuroscience
- Infectious Diseases
- Neurology
Background:
- Diagnosis of HIV-1-associated cognitive-motor disorders (MCMD/HAD) presents clinical challenges.
- Exclusion of other neurological conditions is critical before diagnosing HIV-1 cognitive impairment.
Purpose of the Study:
- To outline diagnostic considerations for HIV-1-associated cognitive-motor disorders.
- To review current and potential therapeutic strategies for MCMD and HAD.
Main Methods:
- Comprehensive medical history and physical examination.
- Neurologic and neuropsychiatric mental status assessments.
- Neuroimaging, lumbar puncture, and serum chemistries to exclude other etiologies.
- Standardized neuropsychological and functional status testing.
Main Results:
- Accurate diagnosis necessitates excluding infections, psychoneurotoxicity, and psychopathology.
- Standardized testing is essential for consistent diagnostic criteria.
- Zidovudine is a proven treatment; other antiretrovirals show promise.
Conclusions:
- Differential diagnosis is key for MCMD/HAD.
- Antiretroviral therapy is the cornerstone of treatment.
- Future research should explore immunomodulatory, neurotransmitter, and nutritional interventions.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...